Every year, millions of footsteps echo through the halls of Eye Care Practices (ECPs) across the nation, belonging to patients seeking relief from the persistent scourge of Dry Eye Disease (DED). It’s not just a few; a staggering 45% of all patient visits are tied to this condition in the US1. That could potentially be a sizeable chunk of your practice’s daily schedule devoted to addressing blurry visions and itchy, uncomfortable eyes. Yet often, a lasting solution for these patients remains elusive, and there are a few reasons why. 

The Revolving Door of Dry Eye Management

Frustration can build up like a storm both in you and your patients as you cycle through treatment after treatment option with only fleeting glimpses of relief. This revolving door isn’t just tiresome—it’s a risk. Without a breakthrough, patients might start looking beyond your practice for answers, drawn by the promise of a cure. Statistics paint a clear picture: patients typically hop between 3.2 practices before they find any real relief, an unsettling trend for any dedicated practitioner2.

The High Cost of Inadequate Solutions

If you’ve gone through this cycle before, then you likely know that current solutions on the market often feel like choosing between a rock and a hard place. High-cost devices with no guarantee of return on investment or treatments that make a sizable dent in patients’ wallets — neither of these options align well with the ethos of patient-first care. It’s a tough sell to the patient and a burden on your practice’s resources.

The Need for a Better Alternative

Imagine if there was a way to stop that revolving door. If there was an alternative, more cost-effective option that you could easily explain and justify to your patients. An option that not only addresses the symptoms but also targets the underlying causes of DED with a clear, understandable mechanism. Wouldn’t you want to explore that stopper?

The MGrx System presents that understandable approach to treating Dry Eye, focusing on restoring Meibomian gland function, a common underlying cause of the condition. MGD occurs when the meibomian glands in the eyelids, which secrete oils essential for a healthy tear film, become blocked or dysfunctional. Restoring the function of these glands is crucial for lasting relief from Dry Eye. In just a 12-minute treatment with three interchangeable tips, the MGrx system can begin to restore the Meibomian Gland.

Here’s How It Works:

  • Thermal Debridement: The treatment begins by gently warming the eyelid margins to soften the hardened oils clogging the gland openings. This process not only clears these obstructions but also prepares the glands for more effective and deeper treatment, setting the stage for enhanced glandular health and function.
  • Thermal Massage: Following debridement, the second tip applies targeted heat in a massaging action, which helps to further loosen the meibomian glands’ blockages. The warmth increases blood flow to the area, promoting healing and the production of healthy, functional oils necessary for a stable tear film and comfortable eye surface.
  • Thermal Expression: The final tip uses controlled pressure to carefully express the now-loosened oils from the glands. This ensures that the oils can freely flow into the tear film, effectively stabilizing it and providing long-term relief from the dryness and discomfort associated with MGD. This expression process is crucial for restoring normal gland function and preventing future blockages.

 

Close the Revolving Door on Dry Eye Today

The MGrx System offers a transformative solution for both patients and ECPs. It’s not just about managing symptoms; it’s about breaking the cycle of ineffective treatments and providing an affordable pathway to significant, sustained improvement. That’s why for a limited time, the MGrx System is being offered to all ODs on Facebook with a special $2,500 discount. This exclusive sale ends on June 15th, so don’t miss the opportunity to enhance your practice’s capabilities and offer your patients the relief they’ve been searching for.


2 (the 3.2 ECPs one) is McMurren et al., (2023), Open Ophthalmology Journal, MGrx- A Novel Multi-modal Thermal Device…, Oct. 20, 2023. https://openophthalmologyjournal.com/VOLUME/17/ELOCATOR/e187436412308280/FULLTEXT/

 

RELATED:

Limited Time Offer – Save $2,500 on the New MGrx System: Relief from MGD and Dry Eye in One Treatment